Article

A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder

2023-01-30

Abstract excerpt

This 6-month, double-blind, randomized, Phase-3 clinical trial in Alcohol Use Disorder (AUD; n = 303) tested ondansetron 0.33 mg/twice daily (AD04) vs placebo in reducing the Percentage of Heavy Drinking Days (PHDD) among a genetic subgroup with variations at the serotonin transporter and 5-HT3A/5-HT-3B receptors who consumed < 10 Standard Drinks/Drinking Day (DDD) (heavy drinkers) or ≥ 10 DDD (very heavy drinkers...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5b23d37b-6186-55f1-873e-07feb1404a5e
DOI: 10.21203/rs.3.rs-2389870/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use DisorderDOI 10.21203/rs.3.rs-2389870/v1Read

A Prospective Pharmacogenetic Phase 3 Clinical Trial of Low-Dose Ondansetron (A 5-HT3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use DisorderSemantic proximity Read

A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use DisorderSemantic proximity Read

Commentary on Efficacy and Safety of Low dose ondansetron as a prospective precision medicine to treat alcohol use disorder phenotypes.Semantic proximity Read

Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.Semantic proximity Read

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.Semantic proximity Read

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.Semantic proximity Read

Advances in Medications and Tailoring Treatment for Alcohol Use DisorderSemantic proximity Read

Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.Semantic proximity Read

Serotonergic agents and alcoholism treatment: a simulation.Semantic proximity Read

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics studySemantic proximity Read

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read

Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1Semantic proximity Read